| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000016105 |
| Receipt No. | R000018706 |
| Official scientific title of the study | Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI) |
| Date of disclosure of the study information | 2015/01/15 |
| Last modified on | 2016/12/17 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI) | |
| Title of the study (Brief title) | Prospective randomized controlled study of CRRT hemofilters for the treatment of acute kidney injury (AKI) | |
| Region |
|
|
| Condition | |||
| Condition | Acute kidney injury (AKI) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To compare the clinical effects of CRRT hemofilters with different membrane materials and sizes for the treatment of acute kidney injury. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 28-day mortality |
| Key secondary outcomes | 60-day mortality.
Changes of SOFA score at 3 and 7 days after CRRT. Changes of plasma IL-6 levels at 1, 3, and 7 days after CRRT. Changes of lactate levels at 1, 3, and 7 days after CRRT. ICU free-days at Day 28. RRT free-days at Day 28. Progression to ESRD requiring maintenance hemodialysis. (subgroup analysis) septic AKI and non-septic AKI. with and without endotoxin removal hemoperfusion therapy. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | CRRT with 1.8m2 PMMA hemofilter (HEMOFEEL CH-1.8W) | |
| Interventions/Control_2 | CRRT with 1.0m2 PMMA hemofilter (HEMOFEEL CH-1.0N) | |
| Interventions/Control_3 | CRRT with 1.0m2 Polysulfone hemofilter (EXCELFLO AEF-10) | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | AKI patients (AKIN criteria stage 1 or more) who required CRRT in ICU | |||
| Key exclusion criteria | - age less than 18
- pregnant women - chronic hemodialysis patients or patients who received RRT before randomization - end stage cancer patients |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Takashi Shigematsu |
| Organization | Wakayama Medical University |
| Division name | Division of Nephrology, Department of Internal Medicine |
| Address | 811-1 Kimiidera, Wakayama City, Wakayama, Japan |
| TEL | 073-441-0639 |
| taki@wakayama-med.ac.jp | |
| Public contact | |
| Name of contact person | Shigeo Negi |
| Organization | Wakayama Medical University |
| Division name | Division of Nephrology, Department of Inerenal Medicine |
| Address | 811-1 Kimiidera, Wakayama City, Wakayama, Japan |
| TEL | 073-441-0639 |
| Homepage URL | |
| shigeon@wakayama-med.ac.jp | |
| Sponsor | |
| Institute | Wakayama Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Toray Industries, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018706 |